<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883762</url>
  </required_header>
  <id_info>
    <org_study_id>20-242</org_study_id>
    <nct_id>NCT04883762</nct_id>
  </id_info>
  <brief_title>Stool Transplant to Control Treatment-related Diarrhea</brief_title>
  <official_title>Fecal Microbiota Transplantation (FMT) for Immune Checkpoint Inhibitor (ICI)-Related Diarrhea: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, effectiveness, and feasibility of a treatment called fecal&#xD;
      microbiota transplantation (FMT) to reduce the symptoms of ICI-related diarrhea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, non-randomized pilot trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of fecal microbiota transplantation (FMT)-related adverse events</measure>
    <time_frame>for 7 days after each FMT</time_frame>
    <description>will be grading according to CTCAE 5.0.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Fecal Microbiota Transplantation (FMT)</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>Undergo FMT via colonoscopy.</description>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Patients treated with immune checkpoint inhibitors (ICI), including anti-CTLA-4,&#xD;
             anti-PD-1 and anti-PDL-1 therapy for any malignant indication&#xD;
&#xD;
          -  Patients who develop diarrhea ≥ Grade 2 attributed to ICI, that persists despite&#xD;
             treatment with corticosteroids for at least 72 hours and/or at least one dose of a&#xD;
             biologic medication, such as infliximab or vedolizumab, with symptoms that persist or&#xD;
             recur at least 72 hours post-infusion&#xD;
&#xD;
          -  Patients who develop diarrhea ≥ Grade 2 attributed to ICI and who have a&#xD;
             contraindication to immunosuppressive treatment will also be eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active GI infection, including untreated viral, bacterial or fungal or alternative&#xD;
             identified cause(s) of diarrhea.&#xD;
&#xD;
          -  Antibiotic exposure within 48 hours prior to FMT&#xD;
&#xD;
          -  Expected prolonged compromised immunity&#xD;
&#xD;
               -  Known HIV infection with CD4 count &lt;240&#xD;
&#xD;
               -  ANC &lt;1000/mm3 (use of growth factors to raise ANC is acceptable)&#xD;
&#xD;
          -  Seronegative for EBV or CMV (i.e. EBV IgG negative or CMV IgG negative)&#xD;
&#xD;
          -  Contraindications to anesthesia for procedure&#xD;
&#xD;
               -  Serious cardiopulmonary comorbidities&#xD;
&#xD;
               -  Inability to tolerate anesthesia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
               -  Pregnant patients will be excluded from this study&#xD;
&#xD;
               -  Women of childbearing potential should not have plans to became pregnant or&#xD;
                  breastfeed an infant and must agree to use a highly effective method of birth&#xD;
                  control until 2 months after treatment with FMT (e.g. barrier method, oral or&#xD;
                  parenteral contraceptives, a vasectomized partner, or abstinence from sexual&#xD;
                  intercourse)&#xD;
&#xD;
          -  Severe food allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Faleck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Faleck, MD</last_name>
    <phone>212-639-3904</phone>
    <email>faleckd@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Mendelsohn, MD</last_name>
    <phone>212-639-8152</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Faleck, MD</last_name>
      <phone>212-639-3904</phone>
    </contact>
    <contact_backup>
      <last_name>Robin Mendelsohn, MD</last_name>
      <phone>212-639-8152</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Checkpoint Inhibitor (ICI)-Related Diarrhea</keyword>
  <keyword>20-242</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

